Matt P Marinkovich
Associate Professor of Dermatology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matt P Marinkovich as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:15 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07011589 · Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)M. Peter Marinkovich · not yet recruiting · Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa · principal investigator
- Ph1/Ph2NCT06834035 · Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaM. Peter Marinkovich · recruiting · Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:15 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 170 citationsRCR 5.5
- Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.N Engl J Med · 2022160 citationsRCR 12.5
- In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.Nat Med · 2022127 citationsRCR 9.8
- Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.J Clin Invest · 201796 citationsRCR 3.8
- Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.JCI Insight · 201989 citationsRCR 3.7
- A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.J Am Acad Dermatol · 201385 citationsRCR 2.8
- Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.Orphanet J Rare Dis · 202241 citationsRCR 3.0
- 29 citationsRCR 8.2
- Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.Am J Clin Dermatol · 202517 citationsRCR 6.7